SYRE
Spyre Therapeutics
$100.04
−$2.09 (−2.05%)Jul 27, 2026
Key metrics
The numbers that frame SYRE today
- Market cap
- $8.69B
- P/E (TTM)
- -48.4
- EV / FCF
- -46.3
- ROIC
- -36.2%
- Div yield
- 0%
- Debt / equity
- 0.0
- 52wk Low
- $14.51
- 52wk High
- $105.09
Growth
Revenue and earnings trend for SYRE
RevenueNet income
See the full growth breakdown
Revenue and earnings trends, margins and the multi-year trajectory - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inCash flow & returns
Free cash flow and financial health
Free cash flowNet debt
See the full cash-flow picture
Free cash flow detail, returns on capital and the balance-sheet trend - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inInsider trading
Recent insider buying and selling activity
PurchasesSales
Unlock every insider trade
See who is buying and selling, how much, and when - updated as new filings land.
Create a free accountFree foreverNo card required
Already a member? Log inFrequently asked questions
Plain-English answers about SYRE
Is Spyre Therapeutics a good buy?
Hold. Spyre Therapeutics has excellent momentum, but poor quality makes the setup mixed. Growth looks poor. That could put pressure on the long-term business case. We think Spyre Therapeutics is selling at a high price.
What is the market capitalization of SYRE?
Spyre Therapeutics's market capitalization is $8.69B.
What is the P/E ratio for SYRE stock?
Spyre Therapeutics's current P/E ratio is -48.4.
What is the 52-week high for SYRE stock?
The 52-week high for Spyre Therapeutics is $105.09. The current close of $100.04 is 4.8% below that high.
What is the 52-week low for SYRE stock?
The 52-week low for Spyre Therapeutics is $14.51. The current close of $100.04 is 589.7% above that low.
Does SYRE stock pay dividends?
Spyre Therapeutics does not currently show a dividend per share in the company data.
What is the Debt / Equity ratio for SYRE?
Spyre Therapeutics's Debt / Equity ratio is 0.